急性缺血性脑卒中的溶栓治疗：过去与未来。
Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future.
机构信息
Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
Department of Biochemistry, Showa University School of Medicine, Shinagawaku, Tokyo 142-8555, Japan.
出版信息
Curr Pharm Des. 2019;25(3):242-250. doi: 10.2174/1381612825666190319115018.
BACKGROUND
Thromboembolic ischemic stroke, which is mainly caused by hypertension, as well as plasma dyslipidemia, arterial fibrillation and diabetes, is a leading cause of death in the US and other countries. Numerous clinical trials for thrombolytic drugs, which aimed to pharmacologically dissolve thrombi, were conducted in the 1950s, when the first thrombolytic therapy was performed.
METHODS
In this study, we summarize the pathophysiologic features of ischemic stroke, and the history of thrombolytic therapy, and discuss the recent progress that has been made in the ongoing development of thrombolytic drugs.
CONCLUSION
Thrombolytic therapy is sometimes accompanied by harmful hemorrhagic insults; accordingly, a window of time wherein therapy can safely be performed has been established for this approach. Several basic and clinical studies are ongoing to develop next-generation thrombolytic drugs to expand the time window.
背景
血栓栓塞性缺血性中风主要由高血压以及血浆血脂异常、动脉颤动和糖尿病引起，是美国和其他国家的主要死亡原因。在 20 世纪 50 年代首次进行溶栓治疗时，进行了许多针对溶栓药物的临床试验，旨在通过药理学方法溶解血栓。
方法
在这项研究中，我们总结了缺血性中风的病理生理特征以及溶栓治疗的历史，并讨论了目前正在进行的溶栓药物开发方面的最新进展。
结论
溶栓治疗有时会伴随有害的出血性损伤；因此，已经为这种方法建立了一个可以安全进行治疗的时间窗口。目前正在进行一些基础和临床研究，以开发新一代溶栓药物来扩大时间窗口。
Zotero 插件